• 1. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 2. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 3. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 4. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 5. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Oxazinanes 1,2-oxazinanes

Introduction to 3-(1,2-oxazinan-2-yl)propanoic Acid Hydrochloride (CAS No. 1185298-71-8)

3-(1,2-oxazinan-2-yl)propanoic Acid Hydrochloride, identified by the Chemical Abstracts Service Number (CAS No.) 1185298-71-8, is a compound of significant interest in the field of pharmaceutical chemistry and bioorganic synthesis. This molecule, featuring a 1,2-oxazinan-2-yl moiety linked to a propanoic acid backbone and its hydrochloride salt form, has garnered attention due to its structural complexity and potential biological activities. The unique structural framework of this compound positions it as a valuable scaffold for the development of novel therapeutic agents, particularly in the context of targeting complex biological pathways.

The 1,2-oxazinan-2-yl group is a heterocyclic structure that introduces both rigidity and functional versatility to the molecule. This motif has been explored in various pharmaceutical applications due to its ability to modulate interactions with biological targets. The propanoic acid moiety provides a site for further derivatization, enabling the synthesis of analogues with tailored pharmacokinetic and pharmacodynamic properties. The hydrochloride salt form enhances the solubility and stability of the compound, making it more suitable for formulation into pharmaceutical products.

In recent years, there has been growing interest in the development of molecules that can interact with protein-protein interactions (PPIs) or other complex biological targets. The 1,2-oxazinan-2-yl group has been shown to be particularly effective in disrupting or modulating such interactions, making it a promising feature for drug design. Studies have demonstrated that this moiety can interfere with key binding pockets on target proteins, thereby inhibiting or activating specific signaling pathways. This capability is particularly relevant in the context of diseases driven by aberrant protein-protein interactions, such as certain cancers and inflammatory disorders.

Moreover, the propanoic acid component of 3-(1,2-oxazinan-2-yl)propanoic Acid Hydrochloride provides a handle for further chemical modifications. For instance, introducing carboxylic acid derivatives or amides can enhance binding affinity or alter metabolic stability. These modifications are crucial for optimizing drug candidates for clinical use. The hydrochloride salt form not only improves solubility but also ensures consistent drug delivery properties, which are essential for therapeutic efficacy.

Recent advancements in computational chemistry and molecular modeling have further facilitated the design of molecules like 3-(1,2-oxazinan-2-yl)propanoic Acid Hydrochloride. These tools allow researchers to predict binding affinities and identify potential lead compounds with high precision. By leveraging these technologies, scientists have been able to accelerate the discovery process and identify promising candidates for further investigation. This approach has been particularly effective in targeting difficult-to-drug proteins that play critical roles in disease mechanisms.

The potential applications of 3-(1,2-oxazinan-2-yl)propanoic Acid Hydrochloride extend beyond traditional small-molecule drug development. It has shown promise as a building block for peptidomimetics and other bioconjugates designed to interact with biological targets in novel ways. These conjugates can offer improved selectivity and reduced off-target effects compared to conventional small molecules. Additionally, the compound’s ability to cross the blood-brain barrier makes it an attractive candidate for treating neurological disorders.

In clinical research, 3-(1,2-oxazinan-2-yl)propanoic Acid Hydrochloride is being evaluated in preclinical studies to assess its efficacy and safety profiles. Initial results suggest that it exhibits potent activity against certain disease models while maintaining good tolerability. These findings are encouraging and warrant further investigation into its therapeutic potential. Collaborative efforts between academic institutions and pharmaceutical companies are essential for translating these findings into clinical trials and ultimately bringing new treatments to patients.

The synthesis of 3-(1,2-oxazinan-2-yl)propanoic Acid Hydrochloride presents unique challenges due to its complex structural features. However, advances in synthetic methodologies have made it more feasible to produce this compound on a scalable basis. Techniques such as transition-metal-catalyzed reactions and asymmetric synthesis have been employed to construct the desired framework efficiently. These methods not only improve yield but also enable access to enantiomerically pure forms of the compound, which are critical for pharmaceutical applications.

The future direction of research on 3-(1,2-oxazinan-2-yl)propanoic Acid Hydrochloride is likely to focus on expanding its therapeutic applications and optimizing its pharmacological properties. Exploration of novel derivatives and analogues will be key to unlocking its full potential as a therapeutic agent. Additionally, investigating its mechanism of action will provide deeper insights into how it interacts with biological targets and modulates disease pathways.

In conclusion,3-(1,2-oxyzianan - 20 yl ) - propionic acid hydrocholride ( CAS NO . 1185298 - 71 - 8 ) is a promising compound with significant potential in pharmaceutical research . Its unique structural features , coupled with recent advances in drug discovery technologies , make it an attractive candidate for further development . As research continues , we can expect to see more applications emerge , offering hope for new treatments against various diseases .

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)